Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Drug-related challenges following primary total hip and knee arthroplasty

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Fast-track revision knee arthroplasty.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. High-dose steroids in high pain responders undergoing total knee arthroplasty: a randomised double-blind trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Temporal trends in utilization of transcatheter aortic valve replacement and patient characteristics: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The aim of this study was to validate registration of pharmacological treatment in the Danish Hip Arthroplasty Register (DHR) and Danish Knee Arthroplasty Register (DKR). We conducted a population-based study in the Capital Region of Denmark, January 2012 to April 2016. Positive predictive value (PPV) and sensitivity were calculated with 95% confidence intervals (CI) for antithrombotic, antihemorrhagic and antibiotic treatment registered in the DHR and DKR using electronic health records as the reference standard. For the DHR, the PPV and sensitivity were 77.9% (95% CI: 77.2-78.6) and 99.6% (95% CI: 99.4-99.7) for antithrombotic treatment, 70.9% (95% CI: 70.1-71.7) and 97.4% (95% CI: 97.1-97.7) for antihemorrhagic treatment, and 82.9% (95% CI: 82.2-83.5) and 99.4% (95% CI: 99.3-99.5) for antibiotic treatment, respectively. For the DKR, the PPV and sensitivity were 80.6% (95% CI: 79.8-81.4) and 99.6% (95% CI: 99.4-99.7) for antithrombotic treatment, and 84.4% (95% CI: 83.7-85.1) and 100.0% (95% CI: 99.9-100.0) for antibiotic treatment, respectively. The PPV and sensitivity for overall pharmacological treatment registered in the DHR and DKR were generally high and acceptable for use in research.

OriginalsprogEngelsk
TidsskriftBasic & clinical pharmacology & toxicology
Vol/bind128
Udgave nummer3
Sider (fra-til)455-462
Antal sider8
ISSN1742-7843
DOI
StatusUdgivet - mar. 2021

ID: 61103974